ADPT
Adaptive BiotechnologiesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
If MRD commercial demand accelerates, reimbursement outcomes improve, and reported results beat cautious expectations, multiple expansion plus revenue growth could lift shares toward and above $22 within 12 months.
Posture
Defensive
Lead driver
Sentiment
What changed
2 setup hits (3d) with net bullish as of 2026-06-03.
What can break
Competition and pricing pressure in diagnostics
Momentum
19
Value
41
Sentiment
60
Setup hits (3d)
2 · Net Bullish
AI TargetsBase $18.00 · Bull $22.00 · Bear $8.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-16 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bullish
Target $20.86
Why
Momentum19 · Δ7d +4.1
Value41 · Δ7d +0.1
Sentiment60 · Δ7d -7.8
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
19
34% active weight
Current posture
7d trendImproving
Δ7d
+4.1
Δ21d
+1.4
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
60
33% active weight
Current posture
7d trendSoftening
Δ7d
-7.8
Δ21d
-5.2
Why this grade
Composite grade D. Momentum 18.6 / Value 41.1 / Sentiment 60.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$2.42B
Beta
2.18
Shares Out
152.67M
P/E (TTM) · Derived
-40.5
P/S (TTM)
9.77
P/FCF (TTM) · Derived
-38.59
Rev YoY
+102.4%
EPS YoY
+126.9%
Gross Margin
+71.8%
Op Margin
-30.9%
Net Debt
-$89.02M
Current Ratio
3.38
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology